Fresita Proteins Ltd
Fresita Proteins Ltd (FRESITA) last reported results for the quarter ended Jun 2026, with sales of ₹12.99 crore and net profit of ₹1.66 crore. The stock last traded at ₹141, a market capitalisation of ₹126 crore, on a P/E of 45.4. Over the past 52 weeks the stock has ranged between ₹60 and ₹175. Figures are as of 9 Oct 2026 and are not real time.
Fresita Proteins Ltd share price and key metrics
- Current price
- ₹141
- Market cap
- ₹126 cr
- Stock P/E
- 45.4
- Book value
- ₹96
- ROE
- 1.02%
- ROCE
- 1.45%
- Dividend yield
- 0.00%
- 52w high / low
- 175/60.0
Metrics as of 9 Oct 2026. Not real time.
Track Fresita Proteins Ltd
Cruxal reads every Fresita Proteins Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Fresita Proteins Ltd growth and returns
- 10 Years
- 23%
- 5 Years
- 7%
- 3 Years
- 41%
- TTM
- -48%
- 10 Years
- 17%
- 5 Years
- 90%
- 3 Years
- 157%
- TTM
- 813%
- 10 Years
- %
- 5 Years
- 30%
- 3 Years
- 49%
- 1 Year
- 26%
- 10 Years
- 0%
- 5 Years
- 1%
- 3 Years
- 1%
- Last Year
- 1%
Fresita Proteins Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹12.99 cr, up 18.6% from ₹10.95 cr a year earlier. Net profit turned positive at ₹1.66 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.14 | 24.05 | 0 | 10.95 | 4.3 | 0.25 | 0.65 | 12.99 |
| Expenses | 0.03 | 23.95 | 0.1 | 11.44 | 4.01 | 0.37 | 0.05 | 16.26 |
| Operating profit | 0.11 | 0.1 | -0.1 | -0.49 | 0.29 | -0.12 | 0.6 | -3.27 |
| OPM % | 78.57% | 0.42% | — | -4.47% | 6.74% | -48.00% | 92.31% | -25.17% |
| Other income | 0 | 0 | 0 | 0 | 0.11 | 0 | 0.24 | 5.48 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.11 | 0.1 | -0.1 | -0.49 | 0.4 | -0.12 | 0.84 | 2.21 |
| Tax % | 0.00% | 0.00% | 20.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24.89% |
| Net profit | 0.11 | 0.1 | -0.11 | -0.49 | 0.4 | -0.12 | 0.84 | 1.66 |
| EPS (₹) | 0.64 | 0.58 | -0.64 | -2.84 | 2.32 | -0.70 | 0.94 | 1.85 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Fresita Proteins Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.18 | 5.65 | 7.22 | 5.4 | 11.36 | 10.76 | 5.8 | 1.3 | 24.18 | 16.16 | 18.19 |
| Operating profit | -0.17 | -0.35 | -0.11 | 0.09 | -0.02 | 0.26 | -0.15 | -0.15 | 0.02 | 0.29 | -2.5 |
| OPM % | -2.75% | -6.19% | -1.52% | 1.67% | -0.18% | 2.42% | -2.59% | -11.54% | 0.08% | 1.79% | -13.74% |
| Net profit | -0.13 | -0.33 | -0.12 | 0.03 | -0.02 | 0.31 | -0.03 | 0.02 | 0.01 | 0.45 | 2.78 |
| EPS (₹) | -0.75 | -1.91 | -0.70 | 0.17 | -0.12 | 1.80 | -0.17 | 0.12 | 0.06 | 0.50 | 4.41 |
TTM is the trailing twelve months to the most recent quarter.
Fresita Proteins Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 9.75 |
| Reserves | 0.02 | -0.31 | -0.44 | -0.41 | -0.43 | -0.12 | -0.15 | -0.13 | -0.13 | 76.45 |
| Borrowings | 0.20 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 0.20 | 0.13 | 0.12 | 0.06 | 0.07 | 0.07 | 0.05 | 0.07 | 0.27 | 0.45 |
| Total liabilities | 2.92 | 2.32 | 2.19 | 2.15 | 2.14 | 2.45 | 2.40 | 2.44 | 2.64 | 86.65 |
| Fixed assets | 0.05 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 2.86 | 2.28 | 2.17 | 2.14 | 2.13 | 2.45 | 2.40 | 2.44 | 2.64 | 86.64 |
| Total assets | 2.92 | 2.32 | 2.19 | 2.15 | 2.14 | 2.45 | 2.40 | 2.44 | 2.64 | 86.65 |
As reported by the company. Total assets equal total liabilities by construction.
Fresita Proteins Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.09 | 0.48 | -0.59 | -0.05 | -0.05 | 0.10 | -0.30 | -0.23 | -0.11 | -76.36 |
| Cash from investing | 0.00 | 0.02 | 0.11 | 0.09 | 0.08 | 0.09 | 0.16 | 0.17 | 0.00 | 0.36 |
| Cash from financing | -0.42 | -0.20 | 0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 83.49 |
| Net cash flow | -0.51 | 0.30 | -0.47 | 0.03 | 0.03 | 0.19 | -0.14 | -0.07 | -0.08 | 7.49 |
| Free cash flow | -0.09 | 0.48 | -0.59 | -0.04 | -0.05 | 0.10 | -0.30 | -0.23 | -0.11 | -76.35 |
| CFO / operating profit | 53% | -134% | 536% | -22% | 200% | 38% | 200% | 153% | -550% | -26,331% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Fresita Proteins Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -6.02% | -14.66% | -5.63% | 8.17% | 2.88% | 15.73% | 0.42% | 0.85% | 0.84% | 1.45% |
| Debtor days | 38.98 | 44.58 | 36.40 | 56.10 | 24.74 | 7.12 | 0.00 | 0.00 | 0.00 | 93.51 |
| Inventory days | 64.41 | 28.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days payable | 0.61 | 0.00 | — | — | — | — | — | — | — | — |
| Cash conversion cycle | 102.78 | 73.22 | 36.40 | 56.10 | 24.74 | 7.12 | 0.00 | 0.00 | 0.00 | 93.51 |
| Working capital days | 108.08 | 76.23 | 83.92 | 114.91 | 55.91 | 64.45 | 130.27 | 603.65 | 5.89 | 1,729.23 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Fresita Proteins Ltd shareholding pattern
Promoters held 80.66% at Jun 2026, up from 0.00% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 80.66% |
| Public | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.01% | 19.34% |
| No. of shareholders | 3,047 | 3,004 | 2,964 | 2,941 | 2,938 | 2,928 | 2,924 | 2,897 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Fresita Proteins Ltd corporate filings
- Fresita Proteins Limited submits Scrutinizer Report for AGM held on 30th September 2026, with all resolutions passedAGM/EGMlow impact
Cruxal's analysis: Fresita Proteins Limited has conducted its AGM on 30th September 2026, with all…
Read the full analysis - Fresita Proteins Ltd conducts 35th AGM; no immediate financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Fresita Proteins Ltd held its 35th Annual General Meeting on 30th September 2026 via…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Sarda Proteins Ltd issues clarification regarding recent stock price movementCompany Updatelow impact
Cruxal's analysis: Sarda Proteins Ltd has issued a formal clarification in response to the recent volatility…
Read the full analysis - Sarda Proteins Ltd issues clarification regarding recent stock price movementCompany Updatelow impact
Cruxal's analysis: Sarda Proteins Ltd has issued a formal clarification in response to the recent movement…
Read the full analysis - Sarda Proteins Ltd receives BSE approval for name change effective September 21, 2026Company Updatelow impact
Cruxal's analysis: Sarda Proteins Ltd has received formal approval from the BSE for a change in its company…
Read the full analysis - Sarda Proteins Ltd announces Annual General Meeting (AGM) scheduled for September 8, 2026Company Updatelow impact
Cruxal's analysis: Sarda Proteins Ltd has published a newspaper notice regarding its upcoming Annual General…
Read the full analysis - Sarda Proteins Ltd releases 35th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Sarda Proteins Ltd has filed its 35th Annual Report for the financial year 2025-26. The…
Read the full analysis - Sarda Proteins Limited announces 35th AGM with proposals for significant borrowing and investment limits of 1,000 crore INRAGM/EGMhigh impact
Cruxal's analysis: Sarda Proteins Limited has issued a notice for its 35th Annual General Meeting scheduled…
Read the full analysis - Sarda Proteins Ltd announces date for 35th Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Sarda Proteins Ltd has issued an intimation regarding the scheduling of its 35th Annual…
Read the full analysis - Sarda Proteins Ltd schedules 35th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Sarda Proteins Ltd has issued an intimation regarding the date of its 35th Annual General…
Read the full analysis - Sarda Proteins Limited announces Annual General Meeting (AGM) scheduled for September 30, 2026Board Meetinglow impact
Cruxal's analysis: Sarda Proteins Limited has formally announced the convening of its Annual General Meeting…
Read the full analysis - Sarda Proteins Limited schedules Board Meeting for 7th September 2026 to finalize AGM logisticsBoard Meetinglow impact
Cruxal's analysis: Sarda Proteins Limited has issued a formal intimation under Regulation 29 of SEBI (LODR)…
Read the full analysis - Sarda Proteins Limited Announces Massive 100 Crore Rights Issue, Significantly Exceeding Current Market CapitalizationBoard Meetinghigh impact
Cruxal's analysis: Sarda Proteins Limited has approved a rights issue of equity shares for an amount not…
Read the full analysis - Sarda Proteins Limited issues revised FY26 audited financial results following clerical adjustmentsCompany Updatelow impact
Cruxal's analysis: Sarda Proteins Limited has submitted revised audited financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.